Cardiology

PCSK9 inhibitors reduce lipoprotein (a) production

A new study published today in JACC: Basic to Translational Science sheds light on PCSK9 inhibitors, a new class of low density lipoprotein (LDL) lowering drugs, and their impact on another risk factor for heart disease, ...

Diseases, Conditions, Syndromes

Baricitinib associated with significant improvement in RA

(HealthDay)—For patients with rheumatoid arthritis who have had an inadequate response to methotrexate, baricitinib is associated with significant clinical improvements, compared to either placebo or adalimumab, according ...

Medical research

Greater drop in LDL seen with atorvastatin plus PCSK9 antibody

(HealthDay)—Addition of the fully human serum proprotein convertase subtilisin/kexin 9 monoclonal antibody, SAR236553, to atorvastatin is associated with greater reductions in low-density lipoprotein (LDL) cholesterol levels ...

Cardiology

High TG, low HDL-C levels may help further stratify CHD risk

(HealthDay)—A high fasting triglyceride (TG) level combined with a low high-density lipoprotein cholesterol (HDL-C) level is associated with increased risks of incident coronary heart disease (CHD) and ischemic stroke, ...

Cardiology

Poor response to cholesterol drugs may indicate blocked arteries

If your "bad" cholesterol level stays the same or increases after you take statin drugs, you may have more blocked arteries than people whose levels drop, according to research in the American Heart Association journal Arteriosclerosis, ...

Cardiology

Glucose variation impacts coronary plaque vulnerability

(HealthDay)—For patients with coronary artery disease (CAD) pretreated with lipid-lowering therapy, daily glucose fluctuation may affect coronary plaque vulnerability, according to a study published in the May issue of ...

page 11 from 22